key: cord-0734387-k672k58d
authors: Cavalcante, Francisco Pimentel; Novita, Guilherme Garcia; Millen, Eduardo Camargo; Zerwes, Felipe Pereira; de Oliveira, Vilmar Marques; Sousa, Ana Luiza Lima; Freitas Junior, Ruffo
title: Management of early breast cancer during the COVID-19 pandemic in Brazil
date: 2020-08-16
journal: Breast Cancer Res Treat
DOI: 10.1007/s10549-020-05877-y
sha: b48d8941290f7deb26dfc85611e0bfe60813d0ff
doc_id: 734387
cord_uid: k672k58d

PURPOSE: The COVID-19 pandemic has impacted early breast cancer (EBC) treatment worldwide. This study analyzed how Brazilian breast specialists are managing EBC. METHODS: An electronic survey was conducted with members of the Brazilian Society of Breast Cancer Specialists (SBM) between April 30 and May 11, 2020. Bivariate analysis was used to describe changes in how specialists managed EBC at the beginning and during the pandemic, according to breast cancer subtype and oncoplastic surgery. RESULTS: The response rate was 34.4% (503/1462 specialists). Most of the respondents (324; 64.4%) lived in a state capital city, were board-certified as breast specialists (395; 78.5%) and either worked in an academic institute or one associated with breast cancer treatment (390; 77.5%). The best response rate was from the southeast of the country (240; 47.7%) followed by the northeast (128; 25.4%). At the beginning of the pandemic, 43% changed their management approach. As the outbreak progressed, this proportion increased to 69.8% (p < 0.001). The southeast of the country (p = 0.005) and the state capital cities (p < 0.001) were associated with changes at the beginning of the pandemic, while being female (p = 0.001) was associated with changes during the pandemic. For hormone receptor-positive tumors with the best prognosis (Ki-67 < 20%), 47.9% and 17.7% of specialists would recommend neoadjuvant endocrine therapy for postmenopausal and premenopausal women, respectively. For tumors with poorer prognosis (Ki-67 > 30%), 34% and 10.9% would recommend it for postmenopausal and premenopausal women, respectively. Menopausal status significantly affected whether the specialists changed their approach (p < 0.00001). For tumors ≥ 1.0 cm, 42.9% of respondents would recommend neoadjuvant systemic therapy for triple-negative tumors and 39.6% for HER2 + tumors. Overall, 63.4% would recommend immediate total breast reconstruction, while only 3.4% would recommend autologous reconstruction. In breast-conserving surgery, 75% would recommend partial breast reconstruction; however, 54.1% would contraindicate mammoplasty. Furthermore, 84.9% of respondents would not recommend prophylactic mastectomy in cases of BRCA mutation. CONCLUSIONS: Important changes occurred in EBC treatment, particularly for hormone receptor-positive tumors, as the outbreak progressed in each region. Systematic monitoring could assure appropriate breast cancer treatment, mitigating the impact of the pandemic.

A novel coronavirus (SARS-COV-2) has led to a global health emergency, with the World Health Organization (WHO) ultimately declaring it a pandemic [1] . The transmission and progression of this disease imply that a great number of infected individuals will need hospitalization and possibly admission to intensive care units [2, 3] . On May 11, over 168,000 individuals in Brazil had a confirmed COVID-19 infection and around 11,500 had died from the disease. The southeast and northeast were the regions most affected, with 43% and 34% of the accumulated cases, respectively [4] . Recognition of the seriousness of the situation resulted in the implementation of social distancing measures, with a consequently negative effect on the management of various different diseases [5] .

The management of early breast cancer (EBC), a disease with well-established treatment protocols [6] [7] [8] , also had to be adjusted in order to free up hospital beds and vital hospital supplies for individuals infected by COVID- 19 . Initial reports suggested that cancer patients might be at a greater risk of developing severe symptoms compared to the rest of the population, possibly due to their state of immunosuppression resulting from cancer treatment [9] [10] [11] . Expert groups have drawn up novel protocols for EBC during the pandemic [12] [13] [14] . The treatment of EBC with a low risk of progression, such as ductal carcinoma in situ or invasive hormone-positive tumors, could begin, for example, with neoadjuvant endocrine therapy (NET) [15] . Surgery would then be postponed with no negative effect on disease outcome [16] [17] [18] . Other suggestions include extending the use of neoadjuvant chemotherapy (NACT) to tumors of adverse biology [19, 20] and avoiding major or prophylactic surgeries.

Breast cancer treatment during the pandemic has been much debated in Brazil and worldwide [21] [22] [23] [24] . Multimodal treatment, including upfront surgery associated with adjuvant therapy in most cases, improves prognosis [25] . This online survey aimed to evaluate how Brazilian breast specialists have managed EBC (stage I/II and clinically negative axilla) following publication of emergency treatment protocols [12-14, 23, 24] , at the beginning and during the COVID-19 pandemic, according to EBC subtypes [26] and oncoplastic surgery.

Between April 30 and May 11, 2020, a survey was conducted by e-mailing a questionnaire to 1462 actively practicing physicians affiliated to the Brazilian Society of Breast Cancer Specialists (SBM). A previous pilot test involving 10 associates evaluated the time required to complete the questionnaire and the response rate, with any necessary changes then being incorporated. The recommendations of the American Association for Public Opinion Research were taken into consideration when constructing and applying the questionnaire and evaluating response. In view of the rapid changes triggered by the pandemic, the deadline for returning the questionnaires was short.

The questionnaire dealt with demographic aspects, changes in EBC management at the beginning and during the pandemic, and EBC management as a function of breast cancer subtypes and the oncoplastic surgery performed (see addendum). The first part of the questionnaire focused on the respondent's demographic data including sex, age, board certification as a breast specialist (yes or no) and workplace (general hospital or cancer center). The following aspects of the respondent's workplace were also evaluated: region of the country; type of city (state capital or other city/town); number of inhabitants; confirmed cases of COVID-19 and availability of dedicated COVID-free hospitals/wards for treating other diseases.

To evaluate changes in treatment plans, this survey dealt only with EBC (stages I and II), with clinically negative axilla, since these patients are normally submitted to primary surgery. Breast cancer subtype was based on immunohistochemical findings. Patients with HER2 3 + or HER2 2 + and FISH/SISH-positive tumors were classified as HER2 irrespective of hormone receptor (HR) status. Tumors that were HR-negative and HER2-negative were considered triple-negative (TN), while those expressing HR but that were HER2-negative were considered luminal. The Ki-67 proliferation index was used to sub-classify luminal tumors based on the 2015 St. Gallen Consensus, which suggested a cut-off point of between 20 and 30% [27] : a low proliferation index was considered luminal A (Ki-67 < 20%), while a Ki-67 index > 30% was classified as luminal B. Questions also dealt with menopausal status and its impact on EBC management. The final questions concerned oncoplastic and prophylactic surgery. The questionnaire ended by asking whether the individual had changed their management approach to EBC over the course of the pandemic, since the outbreak occurred at different times and at different degrees of intensity in the different geographical regions of the country, generating social restrictions that increased or decreased as a function of how the outbreak progressed and of the policies implemented in the different states.

The questions allowed a single answer to be selected. The SBM's internal review board approved the study protocol prior to commencement and waived the requirement for informed consent, since the returned survey forms were unidentified.

The results were stratified by degree of priority in accordance with the COVID-19 Pandemic Breast Cancer Consortium: Priority A patients have a condition that is immediately life threatening and for whom a delay would alter prognosis, while Priority B patients are those who do not have an immediately life threatening condition, but for whom treatment should not be delayed until the end of the pandemic, and Priority C patients are those for whom treatment could be deferred [13] . Priority categories for surgical oncology were B1 (HER2 and TN patients), B3/C1 (T1/2 N0 luminal patients) and C3 (prophylactic surgery). According to the recommendations of the consortium, immediate breast reconstruction, partial or total, is not classified into degrees of priority, but should be limited to tissue expander or implant placement. Autologous reconstruction should be deferred. Here, this category is referred to as breast reconstruction.

The statistical analysis was conducted using the Statistical Package for the Social Sciences, version 24.0 (IBM SPSS). To analyze the responses, frequencies and percentages were calculated. The chi-square test was used in the bivariate analysis to evaluate possible management changes at the beginning and during the pandemic. Significance level was set at 5% with a 95% confidence interval (95% CI).

The survey was sent to 1462 physicians affiliated with the SBM, with 503 (34.4%) returning a completed questionnaire. Of these, 271 (53.9%) were male and 229 (45.5%) were female. The most common age group was 31-40 years (172; 34.2%), followed by 41-50 years (157; 31.2%) and 51-60-years (110; 21.9%). Most (324; 64.4%) lived in a state capital city, were board-certified as breast specialists (395; 78.5%) and either worked in an academic institute or one associated with breast cancer treatment (390; 77.5%). The best response rate was from the southeast of the country (240; 47.7%), followed by the northeast (128; 25.4%), south (85; 16.9%), Midwest (35; 7%) and north (15; 3%). Most respondents (355; 70.6%) lived in large cities with over 500,000 inhabitants, while 12 respondents (2.4%) lived in towns with 50,000-100,000 inhabitants and 9 (1.8%) lived in towns with fewer than 50,000 inhabitants. Non-respondents were younger than respondents. Regarding their geographical distribution in the country, more respondents compared to non-respondents came from the northeast and fewer from the southeast. However, there is no statistically significant difference when the southeastern and northeastern regions, those most affected by COVID-19 in Brazil, are evaluated together (p = 0.746) ( Table 1) . No other statistically significant differences were found between the groups.

Overall, 498 respondents (99%) lived/worked in a city/ town with confirmed cases of COVID-19 and 258 (51.3%) reported that there were COVID-free medical establishments in their cities. Overall, 217 (43%) changed their management approach at the beginning of the pandemic, while 351 (69.8%) made changes during the pandemic (p < 0.001) (Fig. 1) .

The southeast of the country (p = 0.005) and the state capital cities (p < 0.001) were associated with changes at the beginning of the pandemic, while being female (p = 0.001) was associated with changes during the pandemic. Being board-certified, having COVID-free hospitals available and working in an academic institute associated with cancer treatment had no significant effect either at the beginning or during the pandemic ( Table 2 ).

In HER2 breast cancer, 107 specialists (21.3%) would recommend neoadjuvant systemic therapy for all cases compared to 132 (26.2%) who would recommend upfront surgery. Overall, 199 specialists (39.6%) would recommend initial systemic therapy in cases of tumors ≥ 1.0 cm, while for 59 (11.7%) the cut-off point for neoadjuvant treatment would be ≥ 0.5 cm. In cases of triple-negative tumors, 96 (19.1%) would recommend NACT for all cases compared to 108 (21.5%) who would recommend upfront surgery. Overall, 216 (42.9%) specialists believed that NACT is the most appropriate option only for tumors ≥ 1.0 cm, while 77 (15.3%) would recommend neoadjuvant therapy in cases of tumors ≥ 0.5 cm (Fig. 2 ).

In cases of HR-positive breast cancer tumors with the best prognosis (Ki-67 < 20%), 241 physicians (47.9%) would recommend NET for 3-6 months for postmenopausal patients compared to 251 (49.9%) who would recommend upfront surgery and 7 (1.4%) who would recommend NACT. While 89 respondents (17.7%) would recommend NET for premenopausal women, 390 (77.5%) would recommend upfront surgery and 20 (4%) would recommend NACT. In the case of HR-positive tumors with a higher proliferation index (Ki-67 > 30%), 171 specialists (34%) would recommend NET for postmenopausal women and 55 (10.9%) would recommend it for premenopausal women. For postmenopausal women, 63 (12.5%) specialists would recommend NACT and 264 

Overall, 427 respondents (84.9%) would not recommend risk-reducing mastectomy, even for patients with BRCA deleterious mutations.

Overall, 319 (63.4%) participants would recommend immediate total breast reconstruction. A definitive implant would be the preferred method of reconstruction for 273 participants (54.3%), while 201 (40%) would recommend temporary tissue expanders and 17 (3.4%) would recommend reconstruction using autologous tissue. A total of 377 respondents (75%) would perform breast-conserving surgery with partial reconstruction, while 272 (54.1%) would contraindicate mammoplasty associated with breast-conserving surgery (Fig. 3) . 

The immunohistochemical classification of breast cancer into subtypes [26] [27] [28] allows different treatment strategies to be adopted. In TN and HER2 tumors, NACT regimens and/ or associated target therapy have contributed to minimizing surgical morbidity and to identifying patients with residual disease for additional adjuvant therapy [29] [30] [31] . On the other hand, the approach with luminal tumors is generally upfront surgery, with the need for chemotherapy being defined according to histopathology, immunohistochemistry and genomic assay [27] . In general, the use of NET has been restricted to exceptional cases [28] . Brazil is a country of continental dimensions, with a widely differing distribution of human and technical resources. The availability of hospital supplies and beds is greater in the southeast of the country where the concentration of COVID-19 cases is greater. The southeast is currently the most severely affected region, with over 840,000 cases (34%), followed by the northeast with 810,000 (33%), the north (393,000; 16%), the Midwest (230,000; 9%) and the south (205,000; 8%) [4, 32, 33] . The concentration of physicians affiliated to the SBM is also greater in the southeast, with the highest response rate in the present study being from that region (48%), followed by the northeast, the south, the Midwest and finally the north, with only 3%. In agreement with the SBM database, most respondents live in state capitals or in cities with more than 500,000 inhabitants, which are also those most affected by COVID-19 [34] .

The onset of the COVID-19 epidemic in Brazil occurred relatively late compared to Europe and North America. Whereas the incidence of the disease was high in Italy and Spain in March, it was only beginning to appear in Brazil at that time, first in the city of São Paulo in the southeast and then spreading unevenly throughout the country [32] . This heterogenous pattern of spread may have resulted in poorer initial compliance by Brazilian breast specialists with the guidelines issued in those countries. Accordingly, 57% of participants did not change their management approach regarding EBC at the beginning of the pandemic, while 70% changed their management approach during the course of the pandemic. At the beginning of the pandemic, changes in management occurred similarly in both sexes and in the different age groups, and irrespective of board certification or workplace. The demographic characteristics most associated with a change in management at the beginning of the pandemic were living in the southeast of the country and in a state capital city, coinciding with the areas in which the incidence of COVID-19 infection was greatest, with an increasing demand for hospital beds and the implementation of restrictive measures by the government. On the other hand, during the pandemic, various state capital cities made an effort to reserve COVID-free hospitals or wards so as to guarantee the admission of elective patients, particularly cancer patients. These initiatives, however, had no effect on the results of this survey.

NET was more commonly indicated for postmenopausal women, both in the case of luminal A (48%) and luminal B tumors (34%). For premenopausal women, the specialists were more likely to recommend NET for cases of luminal A (18%) compared to luminal B tumors (11%). Menopausal status had a significant effect on how these specialists manage EBC. Conversely, although a considerable proportion of respondents suggested a different approach with respect to luminal tumors, upfront surgery remained the most common choice. For premenopausal women, 77.5% of respondents recommended upfront surgery for luminal A tumors and 67% for luminal B tumors. For postmenopausal patients, fewer respondents would recommend upfront surgery, either for luminal A tumors (50%) or for luminal B tumors (52.5%). The pandemic and the emergency recommendations for EBC treatment impacted on the management strategies of Brazilian breast specialists. According to these recommendations [13-15, 23, 35, 36] , HR-positive EBC should preferentially be treated using NET. Some societies have suggested that recommendations for the treatment of EBC should be classified by degree of priority [13, 37] . According to the advice provided in the Ontario Health Pandemic Planning Clinical Guideline for Patients with Cancer [37] , cases of luminal tumors were classified as Priority B, while the COVID-19 Pandemic Breast Cancer Consortium stratified such tumors as Priority B3 (T2 or N1) or C1 (T1N0) [13] . Another cancer organization also suggested that luminal A tumors should be treated initially with NET, while in the case of luminal B tumors, particularly those in which the axilla is positive or clinical stage II, the use of genomic assays could be useful in making this decision [36, 38, 39] . On the other hand, despite the partial compliance of Brazilian breast specialists with NET in the present study, particularly in cases in which the proliferation index is low, it is clear that a good proportion of those interviewed are still reluctant to use this strategy, even in exceptional conditions such as during a pandemic. However, although NET is a treatment that remains under debate, its use has increased in recent years with the publication of studies showing its safety [16-18, 40, 41] .

In HER2 and TN tumors, considerable variations were found in the protocols from the different organizations. In one, TN and HER2 tumors are classified as Priority B1, suggesting NACT for tumors over 2 cm or with affected axillae [13] . Others also suggest NACT without specifying the cut-off point for treatment [32, 33] . The Brazilian Society of Clinical Oncology suggests NACT for tumors over 5 mm or in the case of positive axillae [23] . These differences were reflected in this survey, with 21% of participants recommending NACT for all cases of HER2 tumors and 19% recommending it for all TN tumors. Overall, 40% of respondents considered the cut-off point of 1 cm for an indication of NACT to be appropriate in the case of HER2 tumors, while 43% deemed it appropriate for TN tumors. Conversely, 12% considered a cut-off point of 0.5 cm to be appropriate for NACT in HER2 tumors and 15% for TN tumors. In these subtypes, compliance with the recommendations would appear to be greater, although it is impossible to affirm that there was indeed any change. The prediction of a better pathological response to cytotoxic drugs and targeted therapy, as well as the possibility of selecting cases of residual disease for additional adjuvant therapy, had already rendered neoadjuvant therapy the standard treatment in many cases before the pandemic [29, 30, 42] . Likewise, in our understanding, the fact that one-third of respondents opted for NACT in cases of tumors < 1 cm may represent overtreatment, since there are safe options of de-escalating treatment, as occurs in cases of HER2 tumors [43] . A recent single institution guideline recommended upfront surgery for T1N0 HER2 and TN tumors [44] .

Breast reconstruction constitutes the basic principle in the present-day surgical treatment of breast cancer [45, 46] . Approximately 60% of the participants would recommend total immediate breast reconstruction, with the most commonly suggested technique being definitive implants followed by tissue expanders. For breast-conserving surgery, 75% would recommend partial reconstruction, whereas 54% would contraindicate mammoplasty. Finally, 85% of respondents would not recommend risk-reducing mastectomy for patients with BRCA deleterious mutations. These data agree with the recommendations to avoid or delay major surgery that could prolong hospitalization and increase complications or require further hospital admissions [47] [48] [49] [50] [51] [52] [53] .

There are other surveys that deal with the management of breast cancer [54, 55] . An interesting European study evaluated the changes in EBC management during the pandemic [55] . Unlike the results of the present study, upfront surgery in that study increased in cases of T1 N0 TN and in HER2. Indeed, 67% of respondents considered that chemotherapy increases the risk of developing COVID-19-related complications. In luminal A tumors, 68% recommended NET compared to 48% in the present study (postmenopausal women). These differences may be explained by the improvement in local conditions since this survey was conducted in April.

There are some limitations associated with the present study. Since the data were obtained from a survey, it is impossible to affirm that the behavior encountered in these results would be completely applicable when treatment for actual patients is being recommended. In addition, there is no information on whether the respondents worked in the public or private sector. Another limitation refers to the deadline established for the responses to the questionnaires to be received, which was short; however, the dynamics of the progression of the pandemic could have affected the results if a longer time had been allowed. Nevertheless, the short deadline may have affected the response rate of 34.4%, increasing the likelihood of bias. On the other hand, no significant differences were found between the different geographical regions of the country, or between the SBM database and our sample population, leading us to believe that the sample was indeed representative.

The present findings highlight important changes in the management approach of these breast specialists at the beginning of the pandemic and throughout, particularly with respect to HR-positive tumors. These data may provide further information on EBC treatment in Brazil during the COVID-19 pandemic and may be useful in the perception of treatment and its consequences, permitting adaptation and a return to the conventional guidelines as the outbreak progresses in each region of the country.

Acknowledgements The authors are grateful to Fernanda Pereira Alves and Jéssica Telles Bonavita for their secretary work in providing the relevant data on the SBM members.

Funding None.

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This is a survey study. All of those who answered the questionnaire agreed to participate. The completed survey forms were maintained anonymous.

Electronic survey for breast specialists affiliated to the Brazilian Society of Breast Specialists (SBM) 1 

World Health Organization (2020) WHO Director-General's opening remarks at the media briefing on COVID-19 -11

China Novel Coronavirus Investigating, and Research Team et al (2019) A novel coronavirus from patients with pneumonia in China

Coronavirus infections: more than just the common cold

Ten weeks to crush the curve

National Comprehensive Cancer Network (NCCN) (2020) NCCN Clinical Practice Guidelines in Oncology

Breast Cancer version 4

Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019 et al (2019) Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cancer and coronavirus disease 2019 (COVID-19): facing the "C Words

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan

A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 Pandemic Breast Cancer Consortium

Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE Study

Rationalizing breast cancer surgery during the COVID-19 pandemic

Adapting radiation therapy treatments for patients with breast cancer during the COVID-19 pandemic: hypo-fractionation and accelerated partial breast irradiation to address World Health Organization recommendations

Breast oncology and the COVID-19 pandemic: recommendations from the Brazilian Society of Clinical Oncology (SBOC)

Breast cancer care during the coronavirus pandemic

Progress in adjuvant systemic therapy for breast cancer

Molecular portraits of human breast tumours

Tailoring therapies: improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer

Breast cancer

Adjuvant capecitabine for breast cancer after preoperative chemotherapy

Trastuzumab emtansine for residual invasive HER2-positive breast cancer

Role of axillary surgery after neoadjuvant chemotherapy

Covid-19 Now: a view of the main indicators by Brazilian state

www.covid 19ago ra.com.br. Accessed

ESMO) (2020) ESMO clinical practice guidelines: breast cancer

Suggested treatment modifications in multidisciplinary breast cancer management in the setting of COVID-19

Pandemic planning clinical guideline for patients with cancer

Estimating risk of recurrence for early breast cancer: integrating clinical and genomic risk

Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial

Phase II single arm study of preoperative letrozole for estrogen receptor-positive postmenopausal ductal carcinoma in situ CALGB 40903 (Alliance)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer

Management of breast cancer during the COVID-19 pandemic: a stageand subtype-specific approach

Patient satisfaction and quality of life in breast reconstruction: assessment of outcomes of immediate, delayed, and nonreconstruction

Oncoplastic Breast Consortium consensus conference on nipple sparing mastectomy

Comparison of 2-year complication rates among common techniques for postmastectomy breast reconstruction

Complications of autologous breast reconstruction

Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer

Complications, risk factors, and patients-reported outcomes after skin-sparing mastectomy followed by breast reconstruction in women with BRCA mutations

Direct-to-implant breast reconstruction: higher complication rate vs cosmetic benefits

Flap failure and wound complications in autologous breast reconstruction: a national perspective

Corrigendum to "Predictors of complications following breast reduction surgery: A National Surgical Quality Improvement Program study of 16,812 cases

Assessing the impact of the COVID-19 outbreak on the attitudes and practice of Italian oncologists toward breast cancer care and related research activities

Changes in breast cancer management during the Corona Virus Disease 19 pandemic: an international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST)

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations